Oral Solid Dosage Contract Manufacturing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Oral Solid Dosage Contract Manufacturing Market: By Product Type (Tablets, Capsules, Powders & Granules (MT)), By Release Mechanism (Tablets (Immediate Release, Modified Release, Chewable Tablets, Effervescent Tablets), Capsules (Controlled Release, Enteric Release, Others), Powders & Granules (Uncoated Powders & Granules, Coated Granules)), End User (Big Pharma or Biotech, Small & Medium Size Pharma or Biotech, Emerging or Virtual Pharma, Nutraceutical Companies), and Geography

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Oral Solid Dosage Contract Manufacturing Market size is valued at USD 22,678.1 million in 2021 and expected to grow at a significant CAGR of 6.4% during the forecast period 2022 to 2028. The global market provides a detailed overview and that can be segmented by product type, by release mechanism, and end user. By product type, the market has been segmented into Tablets, Capsules, Powders & Granules (MT). The Tablets segment is likely to be the largest and fastest-growing segment in terms of product type. Based By release mechanism, the market is segmented into Tablets (Immediate Release, Modified Release, Chewable Tablets, and Effervescent Tablets.  Capsules (Controlled Release, Enteric Release, and Others), Powders & Granules (Uncoated Powders & Granules, Coated Granules). The tablets segment is expected to dominate the oral solid dosage contract manufacturing market. Based on the end user, the market has been segregated into Big Pharma or Biotech, Small & Medium Size Pharma or Biotech, Emerging or Virtual Pharma, and Nutraceutical Companies. The Big Pharma or Biotech segment is expected to dominate other segments in the Oral Solid Dosage Contract Manufacturing market according to Precision Business Insights.

Key Development:

In September 2018, Aurobindo acquired the dermatology and oral solids businesses from Sandoz Inc. This will support Sandoz’s strategy of focusing on complex generics, value-added medicines, and biosimilars to achieve sustainable and profitable growth in the U.S. over the long term.

Oral Solid Dosage Contract Manufacturing Market

MARKET SUMMARY
-
6.4% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 5.80%
  • Largest Market–  Asia Pacific
  • Fastest Growing Market– North America

Oral Solid Dosage Contract Manufacturing Market

  • The oral solid dosage contract manufacturing market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The oral solid dosage contract manufacturing market is segmented based on product type,by release mechanism, end user and geography.
Key Players
  • CMIC HOLDINGS Co., LTD.
  • Confab Laboratories Inc.
  • CordenPharma International
  • GENVION Corporation
  • Lonza Group AG
Oral Solid Dosage Contract Manufacturing Market Drivers

Increase in the prevalence of chronic diseases such as diabetes, cardiovascular, cancers, and others is a key factor surge the growth of oral solid dosage form sales. Moreover, CMOs are offering cost-effective services, rise in R&D by the leading pharmaceutical companies, and long-term strategic alliances among the market players are immense boost to the market in the future.


North-America got significant share

Oral Solid Dosage Contract Manufacturing Market

By region, the North America market is expected to witness highest market share during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features Of The Report

  • The global oral solid dosage contract manufacturing market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The oral solid dosage contract manufacturing market report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The oral solid dosage contract manufacturing market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The oral solid dosage contract manufacturing market report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The oral solid dosage contract manufacturing market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Key

Oral Solid Dosage Contract Manufacturing Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The Oral Solid Dosage Contract Manufacturing Market is projected to expand at a CAGR of 6.4% during the forecast period.

The major players in the global oral solid dosage contract manufacturing market are ​​Abbvie Inc., Alcami Corporation, Cambrex Corporation (Halo Pharma), CMIC HOLDINGS Co., LTD., Confab Laboratories Inc. CordenPharma International, GENVION Corporation, Lonza Group AG, Mayne Pharma (Metrics Contract Services), Pfizer Inc., Pharma Tech Industries, Piramal Enterprises Ltd.

North America is the fastest-growing region for Oral Solid Dosage Contract Manufacturing Market


Report

Table Of Content

1. Executive Summary
2. Global Oral Solid Dosage Contract Manufacturing Market Introduction
2.1. Global Oral Solid Dosage Contract Manufacturing Market – Taxonomy
2.2. Global Oral Solid Dosage Contract Manufacturing Market –Definitions
2.2.1. Product
2.2.2. Release Mechanism
2.2.3. End User
3. Global Oral Solid Dosage Contract Manufacturing Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Oral Solid Dosage Contract Manufacturing Market Dynamic Factors – Impact Analysis
3.6. Global Oral Solid Dosage Contract Manufacturing Market – Competition Landscape
4. Global Oral Solid Dosage Contract Manufacturing Market Analysis,2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Oral Solid Dosage Contract Manufacturing Market, By Product, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Tablets
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Capsules
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Powders & Granules (MT)
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Oral Solid Dosage Contract Manufacturing Market Forecast, By Release Mechanism, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Tablets
6.1.1. Immediate Release
6.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. Modified Release
6.1.2.1. Controlled Release
6.1.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.1.3. Market Opportunity Analysis
6.1.2.2. Enteric Release
6.1.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.2.3. Market Opportunity Analysis
6.1.2.3. Others
6.1.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3.3. Market Opportunity Analysis
6.1.3. Chewable Tablets
6.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3.3. Market Opportunity Analysis
6.1.4. Effervescent Tablets
6.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.4.3. Market Opportunity Analysis
6.2. Capsules
6.2.1. Controlled Release
6.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.1.3. Market Opportunity Analysis
6.2.2. Enteric Release
6.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.2.3. Market Opportunity Analysis
6.2.3. Others
6.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3.3. Market Opportunity Analysis
6.3. Powders & Granules (MT)
6.3.1. Uncoated Powders & Granules
6.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.1.3. Market Opportunity Analysis
6.3.2. Coated Granules
6.3.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.2.3. Market Opportunity Analysis
7. Global Oral Solid Dosage Contract Manufacturing Market, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. Big Pharma or Biotech
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Small & Medium Size Pharma or Biotech
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Emerging or Virtual Pharma
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Nutraceutical Companies
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Oral Solid Dosage Contract Manufacturing Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Oral Solid Dosage Contract Manufacturing Market – Opportunity Analysis Index, By Product, Release Mechanism, End User and Region, 2022 – 2028
9. North America Oral Solid Dosage Contract Manufacturing MarketAnalysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. By Product Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Tablets
9.1.2. Capsules
9.1.3. Powders & Granules (MT)
9.2. Release Mechanism Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Tablets
9.2.1.1. Immediate Release
9.2.1.2. Modified Release
9.2.1.2.1. Controlled Release
9.2.1.2.2. Enteric Release
9.2.1.2.3. Others
9.2.1.3. Chewable Tablets
9.2.1.4. Effervescent Tablets
9.2.2. Capsules
9.2.2.1. Controlled Release
9.2.2.2. Enteric Release
9.2.2.3. Others
9.2.3. Powders & Granules (MT)
9.2.3.1. Uncoated Powders & Granules
9.2.3.2. Coated Granules
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Big Pharma or Biotech
9.3.2. Small & Medium Size Pharma or Biotech
9.3.3. Emerging or Virtual Pharma
9.3.4. Nutraceutical Companies
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Oral Solid Dosage Contract Manufacturing Market – Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2022 – 2028
9.6. North America Oral Solid Dosage Contract Manufacturing Market Dynamics – Trends
10. Europe Oral Solid Dosage Contract Manufacturing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. By Product Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Tablets
10.1.2. Capsules
10.1.3. Powders & Granules (MT)
10.2. Release Mechanism Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Tablets
10.2.1.1. Immediate Release
10.2.1.2. Modified Release
10.2.1.2.1. Controlled Release
10.2.1.2.2. Enteric Release
10.2.1.2.3. Others
10.2.1.3. Chewable Tablets
10.2.1.4. Effervescent Tablets
10.2.2. Capsules
10.2.2.1. Controlled Release
10.2.2.2. Enteric Release
10.2.2.3. Others
10.2.3. Powders & Granules (MT)
10.2.3.1. Uncoated Powders & Granules
10.2.3.2. Coated Granules
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Big Pharma or Biotech
10.3.2. Small & Medium Size Pharma or Biotech
10.3.3. Emerging or Virtual Pharma
10.3.4. Nutraceutical Companies
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Oral Solid Dosage Contract Manufacturing Market – Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2022 – 2028
10.6. Europe Oral Solid Dosage Contract Manufacturing Market Dynamics – Trends
11. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. By Product Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Tablets
11.1.2. Capsules
11.1.3. Powders & Granules (MT)
11.2. Release Mechanism Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Tablets
11.2.1.1. Immediate Release
11.2.1.2. Modified Release
11.2.1.2.1. Controlled Release
11.2.1.2.2. Enteric Release
11.2.1.2.3. Others
11.2.1.3. Chewable Tablets
11.2.1.4. Effervescent Tablets
11.2.2. Capsules
11.2.2.1. Controlled Release
11.2.2.2. Enteric Release
11.2.2.3. Others
11.2.3. Powders & Granules (MT)
11.2.3.1. Uncoated Powders & Granules
11.2.3.2. Coated Granules
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Big Pharma or Biotech
11.3.2. Small & Medium Size Pharma or Biotech
11.3.3. Emerging or Virtual Pharma
11.3.4. Nutraceutical Companies
11.4. Country Analysis2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market – Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2022 – 2028
11.6. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market Dynamics – Trends
12. Latin America Oral Solid Dosage Contract Manufacturing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. By Product Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Tablets
12.1.2. Capsules
12.1.3. Powders & Granules (MT)
12.2. Release Mechanism Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Tablets
12.2.1.1. Immediate Release
12.2.1.2. Modified Release
12.2.1.2.1. Controlled Release
12.2.1.2.2. Enteric Release
12.2.1.2.3. Others
12.2.1.3. Chewable Tablets
12.2.1.4. Effervescent Tablets
12.2.2. Capsules
12.2.2.1. Controlled Release
12.2.2.2. Enteric Release
12.2.2.3. Others
12.2.3. Powders & Granules (MT)
12.2.3.1. Uncoated Powders & Granules
12.2.3.2. Coated Granules
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Big Pharma or Biotech
12.3.2. Small & Medium Size Pharma or Biotech
12.3.3. Emerging or Virtual Pharma
12.3.4. Nutraceutical Companies
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Oral Solid Dosage Contract Manufacturing Market – Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2022 – 2028
12.6. Latin America Oral Solid Dosage Contract Manufacturing Market Dynamics – Trends
13. Middle East and Africa Oral Solid Dosage Contract Manufacturing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. By Product Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Tablets
13.1.2. Capsules
13.1.3. Powders & Granules (MT)
13.2. Release Mechanism Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Tablets
13.2.1.1. Immediate Release
13.2.1.2. Modified Release
13.2.1.2.1. Controlled Release
13.2.1.2.2. Enteric Release
13.2.1.2.3. Others
13.2.1.3. Chewable Tablets
13.2.1.4. Effervescent Tablets
13.2.2. Capsules
13.2.2.1. Controlled Release
13.2.2.2. Enteric Release
13.2.2.3. Others
13.2.3. Powders & Granules (MT)
13.2.3.1. Uncoated Powders & Granules
13.2.3.2. Coated Granules
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Big Pharma or Biotech
13.3.2. Small & Medium Size Pharma or Biotech
13.3.3. Emerging or Virtual Pharma
13.3.4. Nutraceutical Companies
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Oral Solid Dosage Contract Manufacturing Market – Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2022 – 2028
13.6. MEA Oral Solid Dosage Contract Manufacturing Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.1. Strategic Dashboard of Top Market Players
14.2.1. ​​Abbvie Inc.
14.2.2. Alcami Corporation
14.2.3. Cambrex Corporation (Halo Pharma)
14.2.4. CMIC HOLDINGS Co., LTD.
14.2.5. Confab Laboratories Inc.
14.2.6. CordenPharma International
14.2.7. GENVION Corporation
14.2.8. Lonza Group AG
14.2.9. Mayne Pharma (Metrics Contract Services)
14.2.10. Pfizer Inc.
14.2.11. Pharma Tech Industries
14.2.12. Piramal Enterprises Ltd.
14.2.13. PNP Pharmaceuticals Inc.
14.2.14. ThermoFisher Scientific Inc. (Patheon N.V.)
14.2.15. Tower Laboratories Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • Abbvie Inc.
  • Alcami Corporation
  • Cambrex Corporation (Halo Pharma)
  • CMIC HOLDINGS Co., LTD.
  • Confab Laboratories Inc.
  • CordenPharma International
  • GENVION Corporation
  • Lonza Group AG
  • Mayne Pharma (Metrics Contract Services)
  • Pfizer Inc.
  • Pharma Tech Industries
  • Piramal Enterprises Ltd.
  • PNP Pharmaceuticals Inc.
  • ThermoFisher Scientific Inc. (Patheon N.V.)
  • Tower Laboratories Ltd.

Description

Oral Solid Dosage Contract Manufacturing Market size is valued at USD 22,678.1 million in 2021 and expected to grow at a significant CAGR of 6.4% during the forecast period 2022 to 2028. The global market provides a detailed overview and that can be segmented by product type, by release mechanism, and end user. By product type, the market has been segmented into Tablets, Capsules, Powders & Granules (MT). The Tablets segment is likely to be the largest and fastest-growing segment in terms of product type. Based By release mechanism, the market is segmented into Tablets (Immediate Release, Modified Release, Chewable Tablets, and Effervescent Tablets.  Capsules (Controlled Release, Enteric Release, and Others), Powders & Granules (Uncoated Powders & Granules, Coated Granules). The tablets segment is expected to dominate the oral solid dosage contract manufacturing market. Based on the end user, the market has been segregated into Big Pharma or Biotech, Small & Medium Size Pharma or Biotech, Emerging or Virtual Pharma, and Nutraceutical Companies. The Big Pharma or Biotech segment is expected to dominate other segments in the Oral Solid Dosage Contract Manufacturing market according to Precision Business Insights.

Key Development:

In September 2018, Aurobindo acquired the dermatology and oral solids businesses from Sandoz Inc. This will support Sandoz’s strategy of focusing on complex generics, value-added medicines, and biosimilars to achieve sustainable and profitable growth in the U.S. over the long term.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX